# Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

> **NCT00911963** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 49 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** VCH-222 or matching placebo
- **DRUG:** VCH-222 or matching placebo
- **BIOLOGICAL:** peginterferon alfa-2a
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT00911963
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911963, "Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00911963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*